- Title
- Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management
- Creator
- Daley-Yates, Peter; Singh, Dave; Igea, Juan M.; Macchia, Luigi; Verma, Manish; Berend, Norbert; Plank, Maximilian
- Relation
- Advances in Therapy Vol. 40, p. 4042-4059
- Publisher Link
- http://dx.doi.org/10.1007/s12325-023-02585-z
- Publisher
- Adis International
- Resource Type
- journal article
- Date
- 2023
- Description
- Introduction: Pharmacological asthma management focuses on the use of inhaled corticosteroid (ICS)-containing therapies, which reduce airway inflammation and provide bronchoprotection, improving symptom control and reducing exacerbation risk. ICS underuse due to poor adherence is common, leading to poor clinical outcomes including increased risk of mortality. This article reviews efficacy versus systemic activity profiles for various adherence patterns and dosing regimens of fluticasone furoate (FF)-containing and budesonide (BUD)-containing asthma therapies in clinical trials and real-world studies. Methods: We performed a structured literature review (1 January 2000–3 March 2022) and mathematical modelling analysis of FF-containing and BUD-containing regular daily dosing in patients with mild-to-severe asthma, as-needed BUD/formoterol (FOR) in mild asthma, and BUD/FOR maintenance and reliever therapy (MART) dosing in moderate-to-severe asthma, to assess efficacy (bronchoprotection) and systemic activity (cortisol suppression) profiles of dosing patterns of ICS use in multiple adherence scenarios. Results: A total of 22 manuscripts were included in full-text review and 18 in the model simulations. Focusing on FF-containing or BUD-containing treatments at comparable adherence rates, regular daily FF or FF/vilanterol (VI) dosing provided more prolonged bronchoprotection and fewer systemic effects than daily BUD, daily BUD/FOR, or BUD/FOR MART dosing, especially in low adherence scenarios. In model simulations and the real-world setting, FF/VI generally provided longer bronchoprotection, lower systemic activity, and greater clinical benefits over BUD/FOR as well as consistently higher adherence. Conclusion: In this literature review and modelling analysis, FF/VI was found to show clinical advantages on asthma control over BUD/FOR. These findings have implications for helping clinicians select the most suitable inhaled therapy for their patients with asthma.
- Subject
- adherence; asthma; bronchoprotection; budesonide; dosing regimen; fluticasone furoate; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1497076
- Identifier
- uon:54297
- Identifier
- ISSN:0741-238X
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 1242
- Visitors: 1225
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|